Document:

EXHIBIT 10.1
                                                                    ------------

                            ASSET PURCHASE AGREEMENT

     This Asset Purchase Agreement (this "Agreement") is made and entered into
as of September 21, 2006 by and among Genotec Nutritionals, Inc., a Delaware
corporation ("Seller"), George Kontonotas, an individual ("Kontonotas"), Joseph
Freedman, an individual ("Freedman"), Susan Blancato, an individual
("Blancato"), (Kontonotas, Freedman, and Blancato shall be collectively referred
to herein as the "Shareholders"), MM(2) Group, Inc. , a New Jersey corporation
("MM2"), and Genotec Acquisition Corporation, a newly-formed, wholly-owned
subsidiary of MM2 ("Buyer").

                                    RECITALS

WHEREAS, the Shareholders own, of record and beneficially, 10,000,000 shares
(the "Company Shares") of the common stock, $0.01 par value, of the Seller,
being all of the issued and outstanding shares of the capital stock of the
Seller;

WHEREAS, the Seller is engaged in the business of selling nutritional
supplements (the "Business");

WHEREAS, the Buyer wishes to purchase the Business and certain other assets of
the Seller;

NOW, THEREFORE, in consideration of the foregoing premises and the mutual
covenants and agreements contained herein, the parties hereto agree as follows:

                                   ARTICLE I.

                                   DEFINITIONS

     1.1 DEFINED TERMS. As used herein, the terms below shall have the following
meanings:

          "Action" shall mean any action, claim, suit, arbitration, inquiry,
subpoena, discovery request, proceeding or investigation, or threat thereof, by
or before any court or grand jury, any governmental or other regulatory or
administrative agency or commission or any arbitration tribunal.

          "Affiliate" shall mean, with respect to any Person, any other Person
directly or indirectly controlling, controlled by or under common control with
such Person and any member, general partner, director, officer or employee of
such Person. For purposes of this definition of Affiliate, "control" shall mean
the power of one or more Persons to direct the affairs of the Person controlled
by reason of ownership of voting stock, contract or otherwise.

          "Brokerage Business" means the business of brokering raw materials,
bulk commodities and ingredients for the benefit of third parties.

          "Damages" shall mean any and all costs, losses, damages, liabilities,
demands, claims, suits, actions, judgments, causes of action, assessments or
expenses, including interest, penalties, fines and attorneys' fees incident
thereto, incurred in connection with any claim for indemnification arising out
of this Agreement and any and all amounts paid in settlement of any such claim.

          "Intellectual Property" shall mean all copyrights, copyright
registrations, proprietary processes, trade secrets, license rights,
specifications, technical manuals and data, drawings, inventions, designs,
patents, patent applications, mask works, tradenames, trademarks, service marks,
product information and data, know-how and development work-in-progress,
customer lists, software, business correspondence and marketing plans and other
intellectual or intangible property.

<PAGE>

          "Knowledge" shall mean an individual shall be deemed to have
"Knowledge" of a particular fact or other matter if such individual is actually
aware of such fact or other matter or if a prudent individual could be expected
to discover or otherwise become aware of such fact or other matter in the course
of conducting a diligent and comprehensive investigation concerning the truth or
existence of such fact or other matter. Seller shall be deemed to have
"Knowledge" of a particular fact or other matter if any officer or other
representative of Seller has Knowledge of such fact or other matter.

          "Person" shall mean any person or entity, whether an individual,
trustee, corporation, general partnership, limited partnership, trust,
unincorporated organization, limited liability company, business association,
firm, joint venture, or governmental agency or authority.

          "Purchased Assets" shall have the meaning stated in Section 2.1 in the
Agreement.

          "Solvent" shall mean that the Seller shall pay its bills in the
ordinary course of business as the bills come due.

          "Taxes" shall mean all taxes, however denominated, including any
interest, penalties or other additions to tax that may become payable in respect
thereof, (i) imposed by any federal, territorial, state, local or foreign
government or any agency or political subdivision of any such government, for
which Buyer could become liable as successor to or transferee of the Software
Assets or which could become a charge against or lien on the Software Assets,
which taxes shall include, without limiting the generality of the foregoing, all
sales and use taxes, ad valorem taxes, excise taxes, business license taxes,
occupation taxes, real and personal property taxes, stamp taxes, environmental
taxes, real property gains taxes, transfer taxes, payroll and employee
withholding taxes, unemployment insurance contributions, social security taxes
and other governmental charges, and other obligations of the same or of a
similar nature to any of the foregoing, which are required to be paid, withheld
or collected, or (ii) any liability for amounts referred to in (i) as a result
of any obligations to indemnify another person.

                                   ARTICLE II.

                           PURCHASE AND SALE OF ASSETS

     2.1 TRANSFER OF PURCHASED ASSETS. Pursuant to the terms and subject to the
conditions of this Agreement, in exchange for the consideration set forth in
Section 2.2 below, at the Closing, Seller shall sell, assign and deliver to
Buyer, and Buyer shall purchase from Seller, the assets listed on Schedule 2.1
(hereinafter collectively referred to as the "Purchased Assets").

     2.2 PURCHASE PRICE. As consideration for the Purchased Assets, Buyer shall
tender Seller the consideration set forth below:

          (a) Ten million (10,000,000) shares of Class A Common Stock of MM(2)
Group, Inc. (the "Buyer's Stock") to Seller's designees as listed on Schedule
2.2. MM2 hereby agrees to file a registration statement with the Securities and
Exchange Commission to register the Buyer's Stock under the Securities Act of
1933 (the "Act") within sixty (60) days from the Closing Date (the "Registration
Statement"). Subsequent to the Securities and Exchange Commission declaring the
Registration Statement effective, MM2 shall have its counsel provide the
appropriate legal opinion to its transfer to remove the restrictive legend
endorsed upon the share certificates of the Buyer's Stock.

     2.3 LIABILITIES OF SELLER. . Pursuant to the terms and subject to the
conditions of this

                                        2
<PAGE>

Agreement, Buyer will assume certain liabilities included on the June 30, 2006
Balance Sheet of Seller and as adjusted in the ordinary course of business as of
the closing date. Such liabilities are listed on Schedule 2.3 herein
(hereinafter collectively referred to as the "Assumed Liabilities").

                                  ARTICLE III.

                                    CLOSING

     3.1 CLOSING. The closing of the transactions contemplated herein (the
"Closing") shall be held at 10:00 a.m. Eastern Standard Time at the offices of
Buyer at 5 Regent Street, Suite 520, Livingston, NJ 07039, on September 21,
2006, or at such other time and place as the parties may agree (the "Closing
Date") provided that all of the Closing conditions set forth in Section 3.3
hereof shall have occurred.

     3.2 DELIVERIES. Together with an executed counterpart of this Agreement,
the following items shall be delivered by the parties at the Closing:

          (a) BY BUYER. Buyer shall deliver:

               (i) a certificate(s) evidencing the Buyer's Stock;

               (ii) the Employment Agreements for each of the Shareholders
               executed by Buyer.

               (iii) Secretary's Certificate of the Seller as set forth in
               Schedule 3.2.(a)(iv)

               (iv) Officer's Incumbency Certificate of Seller as set forth in
               Schedule 3.2(a)(v).

               (v) MM2 shall have purchased Seventy-five Thousand Dollars
               ($75,000) of the Buyer's Series A Preferred Convertible Stock.

          (b) BY SELLER. Seller shall deliver to Buyer:

               (i) one or more Bills of Sale, in form and substance satisfactory
               to Buyer and sufficient to convey the Purchased Assets to Buyer;

               (ii) such electronic and paper copies and representations of the
               Intellectual Property as may in Buyer's reasonable judgment be
               necessary to convey the Intellectual Property to Buyer;

               (iii) the Employment Agreements for each of the Shareholders
               executed by Kontonotas, Freedman, and Blancato respectively;

               (iv) an Assignment of Seller's rights to the corporate name
               "Genotec Nutritionals, Inc."

               (v) Amendment to the Certificate of Incorporation of Genotec
               Nutritionals, Inc. for filing with the Delaware Secretary of
               State to change its name to a name different from and dissimilar
               to Genotec Nutritionals, Inc.

                                        3
<PAGE>

               (vi) Secretary's Certificate of the Buyer as set forth in
               Schedule 3.2(b)(vi).

               (vii) Officer's Incumbency Certificate of Buyer as set forth in
               Schedule 3.2(b)(vii).

               (viii) such other documents and instruments as are reasonably
               necessary to consummate the transactions contemplated hereby.

               (viii) delivery of all consents, approvals, and assignments
               necessary to consummate the transaction contemplated under this
               Agreement including, but not limited to: third party software
               vendors' consents and reseller agreement consents.

               (ix) an assignment of the lease for 450 Commack Road, Deer Park,
               NY

               (x) Termination of sublet to CardioCeuticals LLC for office space
               located at 450 Commack Road, Deer Park, NY.

                                   ARTICLE IV.

                    REPRESENTATIONS AND WARRANTIES OF SELLER

     Seller represents and warrants to Buyer that:

    4.1 ORGANIZATION. Seller is a corporation duly organized, validly existing
and in good standing under the laws of the State of Delaware and has full
corporate power and authority to own, lease and operate its properties and to
carry on its business as it is now being conducted. Seller is duly qualified or
licensed as a foreign corporation to do business, and is in good standing, in
each jurisdiction where the character of the properties owned, leased or
operated by it or the nature of its business makes such qualification or
licensing necessary, except for failures to be so qualified or licensed and in
good standing that would not, individually or in the aggregate, affect the
Purchased Assets in a materially adverse manner.

     4.2 AUTHORIZATION. Seller has all necessary corporate power and authority
and has taken all corporate action necessary to enter into this Agreement, to
consummate the transactions contemplated hereby and to perform its obligations
hereunder. This Agreement has been duly executed and delivered by Seller and is
a valid and binding obligation of Seller, enforceable against it in accordance
with its respective terms subject to the effect of applicable bankruptcy,
insolvency, reorganization, moratorium and other similar laws relating to or
affecting the rights of creditors generally and limitations imposed by equitable
principles, whether considered in a proceeding at law or in equity, and the
discretion of the court before which any proceeding therefor may be brought.

     4.3 BROKERS. (a) The parties acknowledge that a broker's commission will be
due and owing at the Closing (the "Brokers' Commission Fee") to Michael Logerfo
("Logerfo") and/or Raymond Burke ("Burke"). The Brokers' Commission Fee is the
sole responsibility of Buyer. Other than the Logerfo and Burke set forth above,
the Seller and the Shareholders represent that all negotiations relating to this
Agreement and the transactions contemplated hereby have been conducted without
the intervention of any person or entity acting on behalf of Seller in such a
manner as to give rise to any valid claim against the Seller and/or the Buyer
for any broker's or finder's commission, fee or similar

                                        4
<PAGE>

compensation. The Seller and the Shareholders, jointly and severally, shall
indemnify Buyer and MM2 and hold both harmless from any liability or expense
arising from any claim for brokerage commissions, finder's fees or other similar
compensation based on any agreement, arrangement or understanding made by or on
behalf of Seller and/or the Shareholders.

     (b) MM2 hereby agrees to issue 500,000 shares of MM2 Class A Common Stock
     (the "Logerfo's Stock") to Logerfo, or their designees, as complete and
     final payment owed to Logerfo as his Brokers' Commission Fee. Logerfo's
     Stock will reduce the number of shares to be issued as Buyer's Stock. The
     Logerfo's Stock will be endorsed with the restrictive legend set forth in
     Section 8.1(a) herein.

     4.4 LITIGATION, PROCEEDINGS AND APPLICABLE LAW. There are no Actions,
suits, investigations or proceedings, at law or in equity or before or by any
governmental authority or instrumentality or before any arbitrator of any kind,
pending or, to Seller's Knowledge, threatened (a) against Seller which, if
determined adversely against Seller, would have a material adverse effect on
Seller's or Buyer's ability to use the Intellectual Property in the manner in
which it is now being used by Seller or (b) seeking to delay or enjoin the
consummation of the transactions contemplated hereby, except as listed on
Schedule 4.4. There are no outstanding orders, decrees or stipulations issued by
any federal, state, local or foreign, judicial or administrative authority in
any proceeding to which Seller is or was a party relating to the Software
Assets.

     4.5 NO CONFLICT OR VIOLATION. Neither the execution, the delivery of this
Agreement nor the consummation of the transactions contemplated hereby or
thereby will result in (i) a violation of or a conflict with any provision of
the Articles of Incorporation or Bylaws of Seller, (ii) a material breach or
termination of, or a material default under, any term or provision of any
contract to which Seller is a party or an event which, with notice, lapse of
time, or both, would result in any such material breach, such termination or
such material default, or (iii) a material violation by Seller of any Legal
Requirement or an event which, with notice, lapse of time or both, would result
in such a material violation.

     4.6 INTELLECTUAL PROPERTY. Seller owns all rights to the Intellectual
Property without any conflict or infringement of the intellectual property
rights of others. In addition, Seller has taken reasonable steps (including,
without limitation, entering into Confidentiality Agreements with all officers
and employees of and consultants involved in Seller's business) to maintain the
secrecy and confidentiality of and its proprietary rights in, all Intellectual
Property.

          (b) Schedule 4.6(b) lists (i) all patents and patent applications and
all registered copyrights, trade names, trademarks, service marks and other
company, product or service identifiers included in the Intellectual Property,
and specifies the jurisdictions in which each of the foregoing has been
registered, including the respective registration numbers, and/or any
application for any such registration has been filed; (ii) all licenses,
sublicenses and other agreements as to which Seller is a party and pursuant to
which Seller or any other Person is authorized to use any Intellectual Property;
and (iii) all licenses under which Seller is or may be obligated to make royalty
or other payments. Copies of all licenses, sublicenses and other agreements
identified pursuant to clauses (ii) and (iii) above have been delivered by
Seller to Buyer.

          (c) Seller is not in violation in any material respect of any license,
sublicense or agreement described in Schedule 4.6(b). As a result of the
execution and delivery of this Agreement or the performance of Seller's
obligations hereunder, neither Seller nor Buyer shall be in violation in any
material respect of any license, sublicense or agreement described in such
schedule.

                                        5
<PAGE>

          (d) Seller is the sole owner of all necessary right, title and
interest in and to (free and clear of any liens, encumbrances or security
interests) all non-public domain Intellectual Property and has full rights to
the use, sale, license or disposal thereof. Except as expressly set forth in
Schedule 4.6(b), no other Person has any rights with respect to any of the
Intellectual Property, nor is any consent or approval of any third party needed
to fully utilize and exploit the Intellectual Property.

          (e) No claims with respect to the Intellectual Property have been
asserted to Seller, or, to Seller's Knowledge, are threatened by any person, and
Seller knows of no claims (i) to the effect that Seller infringes any copyright,
patent, trade secret, or other intellectual property right of any third party or
violates any license or agreement with any third party, (ii) contesting the
right of Seller to use, sell, license or dispose of any Intellectual Property,
or (iii) challenging the ownership, validity or effectiveness of any of the
Intellectual Property.

          (f) To the Knowledge of Seller, all trademarks, service marks, and
other company, product or service identifiers held by Seller are valid and
subsisting worldwide.

          (g) To the Knowledge of Seller, and except as expressly set forth in
Schedule 4.6(b), there has not been and there is not now any unauthorized use,
infringement or misappropriation of any of the Intellectual Property by any
third party. Seller has not been sued or, to Seller's Knowledge, charged as a
defendant in any claim, suit, action or proceeding that involves a claim of
infringement of any patents, trademarks, service marks, copyrights or other
intellectual property rights that comprise the Intellectual Property. Seller
does not have any infringement liability with respect to any patent, trademark,
service mark, copyright or other intellectual property right of any third party
insofar as the Intellectual Property is concerned.

          (h) No Intellectual Property is subject to any outstanding order,
judgment, decree, stipulation or agreement restricting in any material manner
the licensing thereof by Seller. Seller has not entered into any agreement to
indemnify any other person against any charge of infringement of any
Intellectual Property. Seller has not entered into any agreement granting any
third party the right to bring infringement actions with respect to, or
otherwise to enforce rights with respect to, any Intellectual Property. Seller
has the exclusive right to file, prosecute and maintain all applications and
registrations with respect to the Intellectual Property developed or owned by
Seller.

          (i) Except as set forth in Schedule 4.6(b), no person has a license to
use or the right to acquire a license to use any future version of any product
based on the Intellectual Property or any product based on the Intellectual
Property that is under development, and no agreement to which Seller is a party
will restrict Buyer from charging customers for any such new version or product.

     4.7 ASSETS GENERALLY. Seller holds good and marketable title, license to or
leasehold interest in all of the Purchased Assets and has the complete and
unrestricted power and the unqualified right to sell, assign and deliver the
Purchased Assets to Buyer. Upon consummation of the transactions contemplated by
this Agreement, Buyer will acquire good and marketable title, license or
leasehold interest to the Purchased Assets free and clear of any encumbrances
and there exists no restriction on the use or transfer of the Purchased Assets.
No Person other than Seller has any right or interest in the Purchased Assets,
including the right to grant interests in the Purchased Assets to third parties.

     4.8 Left blank Intentionally

     4.9 RECEIPT OF SHARES ENTIRELY FOR OWN ACCOUNT. This Agreement is made with
Seller in reliance upon Seller's representation, which by Seller's execution of
this Agreement Seller hereby confirms, that the shares being issued to Seller's
designees hereunder are being acquired for

                                        6
<PAGE>

investment for Seller's designees own account, not as a nominee or agent, and
not with a view to the resale or distribution of any part thereof, and that
Seller designees have no present intention of selling, granting any
participation in, or otherwise distributing the same. By executing this
Agreement, Seller further represents that it does not have any contract,
undertaking, agreement or arrangement with any person to sell, transfer or grant
participations to such person or to any third person, with respect to any of the
Buyer's Stock.

     4.10 DISCLOSURE OF INFORMATION. Seller believes that it has received all
the information necessary or appropriate for deciding whether to receive the
Buyer's Stock as part of the consideration for the Purchased Assets. Seller
further represents that its officers and agents have had an opportunity to ask
questions and receive answers from Buyer regarding the terms and conditions
pertaining to the Buyer's Stock and the business, properties, prospects and
financial conditions of Buyer. Seller has arrived at an independent view
concerning the value of Buyer, recognizes that the transactions in which Seller
is acquiring the Buyer's Stock is occurring in an arms' length transaction and
is not relying upon any statements by Buyer as to the value of Buyer or the
Buyer's Stock.

     4.11 SHAREHOLDERS OF SELLER. Kontonotas, Freedman, and Blancato are the
sole shareholders of the Seller.

     4.12 The Seller is Solvent, and is currently paying its outstanding
obligations to vendors, lenders, employees, governmental entities (including tax
authorities), and other third parties as such obligations become due.

     4.13 INVESTMENT INTENT AND ACKNOWLEDGMENT. (a) The Seller and its designees
is acquiring the Buyer's Stock only for his own account, for investment purposes
only, and not with a view to, or for sale in connection with, any distribution
thereof and with no present intention of distribution or reselling any part of
the Buyer's Stock.

          (b) The Seller and its designees hereby acknowledges that the Seller
and its designees have had an opportunity to ask questions of, and receive
answers from persons acting on behalf of the Buyer and MM2 to verify the
accuracy and completeness of the information set forth in such reports filed
with the Securities and Exchange Commission and attached financial statements
prior to the Closing Date and the Seller and its designees hereby acknowledge
that the Seller and its designees have not requested the Buyer and/or MM2 to
provide any additional information which the Buyer and/or MM2 possess or can
acquire without unreasonable effort or expense that is necessary to verify the
accuracy and completeness of the information made available.

                                   ARTICLE V.

                     REPRESENTATIONS AND WARRANTIES OF BUYER

     Buyer hereby represents and warrants to Seller as follows:

     5.1 ORGANIZATION OF BUYER. Buyer is a corporation duly organized, validly
existing and in good standing under the laws of New Jersey and has full
corporate power and authority to own, lease and operate its properties and to
carry on its business as it is now being conducted.

     5.2 AUTHORIZATION. Buyer has all necessary corporate power and authority
and has taken all corporate action necessary to enter into this Agreement to
consummate the transactions

                                        7
<PAGE>

contemplated hereby and thereby and to perform its obligations hereunder. This
Agreement has been duly executed and delivered by Buyer and is a valid and
binding obligation of Buyer, enforceable against it in accordance with its terms
subject to the effect of applicable bankruptcy, insolvency, reorganization,
moratorium, and other similar laws relating to or affecting the rights of
creditors generally and limitations imposed by equitable principles, whether
considered in a proceeding at law or in equity, and the discretion of the court
before which any proceeding therefore may be brought.

     5.3 BROKERS. All negotiations relating to this Agreement and the
transactions contemplated hereby have been conducted without the intervention of
any person or entity acting on behalf of Buyer in such a manner as to give rise
to any valid claim against Seller for any broker's or finder's commission, fee
or similar compensation.

     5.4 CONSENTS AND APPROVALS. No consent, waiver, approval or authorization
of or by, or declaration, filing or registration with, any governmental or
regulatory authority is required to be made or obtained by Buyer in connection
with the execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby.

     5.5 INSURABILITY OF SHAREHOLDERS. Each of the Shareholders hereby
represents and warranties that he/she is in good physical health, and shall
qualify to underwritten at a standard rate for a "key man" life insurance policy
to be purchased by the Surviving Corporation, naming the Surviving Corporation
as the beneficiary. Each of the Shareholders hereby agrees to use commercially
reasonable efforts to assist the Company in applying for such a policy.

                                   ARTICLE VI.

                                CERTAIN COVENANTS

     6.1 COVENANTS OF BOTH PARTIES. Buyer, on the one hand, and Seller, on the
other hand, each covenant to the other that:

          (a) FURTHER ASSURANCES. Each party will cooperate in good faith with
the other and will take all appropriate action and execute any documents,
instruments or conveyances of any kind which may be reasonably necessary or
advisable to carry out any of the transactions contemplated hereunder. From and
after the execution hereof, Seller will promptly refer all inquiries with
respect to the ownership of the Purchased Assets to Buyer and execute such
documents as Buyer may reasonably request from time to time to evidence transfer
of the Purchased Assets to Buyer.

     6.2 SELLER'S COVENANTS.  Seller covenants to Buyer that:

          (a) COOPERATION AND TRANSITION ASSISTANCE. Seller shall use its best
efforts to facilitate the transition of customers, customer support services,
and development, marketing and sales functions related to the Purchased Assets
to Buyer, and shall direct any new inquiries regarding the Purchased Assets to
Buyer or its assignee.

          (b) DOCUMENTATION. Seller shall provide Buyer with full and complete
documentation, both written and computer generated, relating to the Business
that Seller has conducted using the Purchased Assets, including all
correspondence and files relating to their development.

          (c) CHANGE OF CORPORATE NAME. On the Closing Date, the Seller shall
deliver to the

                                        8
<PAGE>

Buyer an Amendment to the Certificate of Incorporation of the Seller for filing
with the Delaware Secretary of State that shall change the name of the Seller to
a name that is not similar to its present name.

     6.3 MM2'S COVENANTS. MM2 covenants to the Seller and the Shareholders
that:

     (a)  ADDITIONAL INVESTMENT IN THE BUYER. MM2 agrees to investment an
          additional Two Hundred and Twenty-five Thousand Dollars ($225,000)
          (the "Additional Investment") through the purchase of the Buyer's
          Series A Convertible Preferred Stock, as requested from time to time
          by the Board of Directors of the Buyer, as they deem appropriate to
          fund the Buyer's working capital needs.

     (b)  DIRECTORS' AND OFFICERS' LIABILITY INSURANCE. For as long as MM2 shall
          keep in force Directors' and Officers', the Directors and Officers of
          the Buyer shall be covered under said policy.

                                  ARTICLE VII.

                                 INDEMNIFICATION

     7.1 INDEMNIFICATION BY BUYER. In the event Buyer (i) breaches or is deemed
to have breached any of the material representations and warranties contained in
Article V herein, or (ii) fails to perform or comply with any of the covenants
and agreements set forth in this Agreement, Buyer shall hold harmless, indemnify
and defend Seller and each of its directors, officers, shareholders, attorneys,
representatives and agents, from and against any Damages, including all court
costs, litigation expenses and reasonable attorneys' fees, incurred or paid by
Seller to the extent such Damages arise or result from a breach by Buyer of any
such representations or warranties or a violation of any covenant in this
Agreement.

     7.2 INDEMNIFICATION BY SELLER AND SHAREHOLDERS.

     (a) Notwithstanding any investigation by Buyer or its representatives,
Seller and the Shareholders, individually, will jointly and severally, indemnify
and hold Buyer, its Affiliates and their respective directors, officers,
employees and agents (collectively, the "Buyer Parties") harmless from any and
all Damages, liabilities, obligations, claims, contingencies, damages, costs and
expenses, including all court costs, litigation expenses and reasonable
attorneys' fees that any Buyer Parties may suffer or incur as a result of or
relating to:

          (i) the breach of any material representation or warranty made by
     Sellers in this Agreement;

          (ii) all Taxes allocable to any taxable period (or any portion
     thereof) ending on or before the Closing Date.;

          (iii) any claim commenced by any third party relating to actions or
     omissions of Seller (or any of their Affiliates) that occurred prior to the
     Closing Date; and/or (iv) any claim or liability not disclosed in the
     financial statements delivered on the Closing Date or incurred in the
     ordinary course of business consistent with past practice .

     (b) Notwithstanding the above, the Buyer shall not seek indemnification
pursuant to this Article VII against one or more of the individual Shareholders
for any act(s) by another individual Shareholder that occurred subsequent to the
Closing Date.

     7.3 NOTIFICATION OF CLAIMS. If any party or parties (the "Indemnified
Party") reasonably believes that it is entitled to indemnification hereunder, or
otherwise receives notice of the assertion

                                        9
<PAGE>

or commencement of any third-party claim, action, or proceeding (a "Third-Party
Claim"), with respect to which such other party or parties (the "Indemnifying
Party") is obligated to provide indemnification pursuant to Section 7.1 or 7.2
above, the Indemnified Party shall promptly give the Indemnifying Party written
notice of such claim for Indemnification (an "Indemnity Claim"). Any claim for
indemnification under this Section 7 must be brought prior to the expiration of
the survival period for the representation and warranty as set forth in Section
9.1. The delivery of such notice of Indemnity Claim ("Claim Notice") shall be a
condition precedent to any liability of the Indemnifying Party for
indemnification hereunder. The Indemnifying Party shall have twenty (20) days
from the receipt of a Claim Notice (the "Notice Period") to notify the
Indemnified Party of whether or not the Indemnifying Party disputes its
liability to the Indemnified Party with respect to such Indemnity Claim.

     7.4 RESOLUTION OF CLAIMS. With respect to any Indemnity Claim involving a
Third-Party Claim, following prompt notification of the Indemnifying Party, the
Indemnified Party shall proceed with the defense of such Third-Party Claim.
During such defense proceedings, the Indemnified Party shall keep the
Indemnifying Party informed of all material developments and events relating to
the proceedings. The Indemnifying Party shall have a right to be present at the
negotiation, defense and settlement of such Third-Party Claim. The Indemnified
Party shall not agree to any settlement of the Third-Party Claim without the
consent of the Indemnifying Party, which consent shall not be unreasonably
withheld. Following entry of judgment or settlement with respect to the Third-
Party Claim, any dispute as to the liability of the Indemnifying Party with
respect to the Indemnity Claim shall be resolved as provided in Section 9.7.

          (b) With respect to any Indemnity Claim not involving a Third-Party
Claim, if the Indemnifying Party disputes its liability within the Notice
Period, the liability of the Indemnifying Party shall be resolved in accordance
with Section 9.7.

          (c) In the event that an Indemnified Party makes an Indemnity Claim in
accordance with Section 7.3 and the Indemnifying Party does not dispute its
liability within the Notice Period, the amount of such Indemnity Claim shall be
conclusively deemed a liability of the Indemnifying Party.

                                  ARTICLE VIII.

              RESTRICTIONS ON MM2 GROUP, INC. CLASS A COMMON SHARES

     8.1 STOCK LEGEND. The Buyer's Stock issued to Seller's designees pursuant
to this Agreement shall be subject to the following restrictions:

          (a) Legends on Stock Certificates. Each certificate representing
shares issued pursuant to this Agreement shall be endorsed with the following
legends:

          THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
          REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"),
          AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR HYPOTHECATED UNLESS
          THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT COVERING
          SUCH SECURITIES, THE SALE IS MADE IN ACCORDANCE WITH RULE 144 OR ITS
          SUCCESSOR RULE UNDER THE ACT, OR THE COMPANY RECEIVES AN OPINION OF
          COUNSEL SATISFACTORY TO THE COMPANY THAT EXEMPTIONS FROM SUCH
          REGISTRATION AND FROM THE PROVISIONS OF ANY APPLICABLE STATE "BLUE
          SKY" LAWS ARE AVAILABLE.

                                       10
<PAGE>

                                   ARTICLE IX.

                                  MISCELLANEOUS

     9.1  SURVIVAL OF REPRESENTATIONS AND WARRANTIES.  The representations,
warranties and indemnities included or provided for in this Agreement or in any
agreement, schedule or certificate or other document or instrument delivered
pursuant to this Agreement will survive the Closing Date for a period of
thirty-six (36) months. No claim may be made by any party hereto unless written
notice of the claim is given within that thirty-six month period; provided,
however, that the foregoing limitation period will not apply to a breach of any
representation, warranty or covenant known to any party before the Closing Date.

     9.2  [Intentionally omitted]

     9.3  COVENANT NOT TO COMPETE.

     A.   For a period of ten (10) years following the Closing Date, Seller will
          not do any of the following activities listed below, either directly
          or indirectly, anywhere in the United States or Canada. In the event
          that Seller improperly compete with Buyer in violation of this Section
          9.3, the period during which they engage in such competition shall not
          be counted in determining the duration of the ten (10) year
          non-compete restriction:

          (a) For purposes of this Section 9.3, "Competitive Activity" shall
          mean any activity relating to, in respect of or in connection with,
          directly or indirectly, any and all products that the Seller offered
          to its customers or anticipated to offer to its customers immediately
          prior to the Closing Date, except: (i) for the Brokerage Business
          conducted by Kontonotas prior to the Closing date and (ii) the
          business of CardioCeuticals LLC and [*the mail order business*] only
          through September 30, 2006.

          (b) The Seller shall not solicit or perform services in connection
          with any Competitive Activity for any current customers of Buyer or
          any party who was a customer during the past two (2) years except as
          otherwise permitted under the Employment Agreements;

          (c) The Seller shall not solicit for employment or employ any then
          current employees employed by Buyer without Buyer's consent; or

     B.   For a period of two (2) years following the Closing Date, the
          Shareholders will not do any of the following activities listed below,
          either directly or indirectly, anywhere in the United States or
          Canada. In the event that the Shareholders improperly compete with
          Buyer in violation of this Section 9.3, the period during which they
          engage in such competition shall not be counted in determining the
          duration of the two (2) year non-compete restriction:

          (a) The Shareholders individually shall not solicit nor perform
          services in connection with any Competitive Activity for any current
          customers of Buyer or any party who was a customer during the past two
          (2) years except as otherwise permitted under the Employment
          Agreements;

          (b) The Shareholders individually shall not solicit for employment nor
          employ any current employees employed by Buyer or Seller without
          Buyer's consent; or

          (c) For a period of two (2) years following the Closing Date, the
          Shareholders individually shall not compete with the Buyer or MM2, in
          any fashion, and shall not work for, advise, be

                                       11
<PAGE>

          a consultant to or an officer, director, agent or employee of or
          otherwise associate with any person, firm, corporation or other
          entity, or hold more than five percent (5%) of the outstanding capital
          stock of any such entity, which is engaged in or plans to engage in a
          Competitive Activity, except for (i) the Shareholders existing equity
          interests in CardioCeuticals, LLC. and (ii) Dr. Freedman's optometry
          practice as permitted and set forth in Section 10(a).H of the
          Employment Agreement between the Buyer and Freedman.

          (d) Notwithstanding anything to the contrary, should (i) MM2 not
          contribute the Additional Investment as set forth in Section 6.3(a)
          within eighteen months (18) from the Closing Date and (ii) the
          individual Shareholder has resigned h is/her employment with the Buyer
          due to MM2's failure to contribute the Additional Investment (the
          `Resigned Shareholders"), then the Resigned Shareholder shall
          thereafter be released from the restrictive covenant set forth in
          Section 9.3.B above.

          (e) Notwithstanding anything to the contrary, Kontonotas may continue
          to conduct and operate his Brokerage Business with those clients
          and/or customers of the Seller that were also clients and/or customers
          of the Seller prior to the Closing Date.

     9.4  PRESS RELEASES AND PUBLIC ANNOUNCEMENTS.  Prior to the Closing Date,
neither the Seller (nor their respective shareholders, officers and directors)
shall issue any press release or make any public announcement concerning the
matters set forth in this Agreement (other than as required by applicable
disclosure rules or regulations) without the consent of the Buyer. Buyer shall
have the right to make such disclosure and announcements as may be required by
the rules and regulations of the Securities and Exchange Commission.

     9.5 ASSIGNMENT. This Agreement shall be binding upon and inure to the
benefit of the parties hereto and their respective successors and assigns. Buyer
may, without need for any consent or notice to Seller, assign all of its rights
and obligations under this Agreement to any Affiliate of Buyer, and such
assignment shall release Buyer of all of its liabilities and obligations to
Seller, provided such liabilities and obligations are fully assumed by Buyer's
assignee.

     9.6 NOTICES. Unless otherwise provided herein, any notice, request,
instruction or other document to be given hereunder by either party to the other
shall be in writing and delivered by telecopy or other facsimile (with receipt
acknowledged) and followed with delivery via an overnight courier service, or
delivered by an overnight courier service, such notice to be effective on the
date such receipt is acknowledged or refused), to the addresses of the parties
appearing on the signature page of this Agreement or to such other place and
with such other copies as either party may designate as to itself by written
notice to the other.

     9.7 CHOICE OF LAW. This Agreement shall be governed under and construed in
accordance with the laws of the State of New York without regard to its choice
of law principles. For purposes of any dispute or controversy arising under this
Agreement or the transactions contemplated hereby, the parties mutually consent
to the exclusive jurisdiction of the courts of the State of New York or the U.S.
Federal District Court for the Eastern District of New York.

     9.8  ENTIRE AGREEMENT; AMENDMENTS AND WAIVERS.  This Agreement, together
with all exhibits and schedules hereto, constitute the entire agreement among
the parties pertaining to the subject matter hereof and supersede all prior
agreements, understandings, negotiations and discussions, whether oral or
written, of the parties. No supplement, modification or waiver of this Agreement
shall be binding unless executed in writing by the party to be bound thereby. No
waiver of any of the provisions of this Agreement shall be deemed or shall
constitute a waiver of any other

                                       12
<PAGE>

provision hereof (whether or not similar), nor shall such waiver constitute a
continuing waiver unless otherwise expressly provided.

     9.9 MULTIPLE COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument. Facsimile signature pages
shall be considered originals.

     9.10 TITLES. The titles, captions or headings of the Articles and Sections
herein are inserted for convenience of reference only and are not intended to be
a part of or to affect the meaning or interpretation of this Agreement.

     9.11 KONTONOTAS, FREEDMAN, AND BLANCATO. Kontonotas, Freedman, and
Blancato, as sole shareholders and officers of the Seller, hereby agree to
guarantee the performance by the Seller of its obligations herein and the
accuracy of the Seller's representations and warranties under this Agreement.
Kontonotas, Freedman, and Blancato hereby agree that the Buyer may look to
Kontonotas, Freedman, and Blancato for performance of the Seller's obligations
herein, including, but not limited to the Seller's obligations under Article
VII.

     9.12 CARDIOCEUTICALS, LLC. and Nutritional Health, LLC, Kontonotas,
Freedman, and Blancato are each shareholders in CardioCeuticals LLC ("Cardio")
and Nutritional Health, LLC ("Nutritional"). Cardio sublets office space from
the Seller.

     Kontonotas, Freedman, and Blancato shall provide notice, as of the Closing
Date, to Cardio and Nutritional that they may fulfill any management function
required of them, if any, up to and including September 30, 2006. Thereafter,
the Shareholders are expressly prohibited from providing any services to Cardio
and Nutritional. After that date, Kontonotas, Freedman, and Blancato will be
employed solely and exclusively, on a full-time basis, for the benefit of Buyer,
except as set forth in each of the Shareholder's respective employment
agreements.

                                       13
<PAGE>

     IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
duly executed on their respective behalf, by their respective officers thereunto
duly authorized, in multiple originals, all as of the day and year first above
written.

Address for Notice:                     GENOTEC  NUTRITIONALS, INC.,
                                        a Delaware corporation
450 Commack Road
Deer Park, NY  11729
                                        By:_______________________
                                           George Kontonotas
                                           President

Address for Notice:                     GEORGE KONTONOTAS
                                        an individual
450 Commack Road
Deer Park, NY  11729
                                        By:_______________________
                                           George Kontonotas

                                        JOSEPH FREEDMAN
Address for Notice:                     an individual

450 Commack Road
Deer Park, NY  11729
                                        By:_______________________
                                           Joseph Freedman

Address for Notice:                     SUSAN BLANCATO
                                        an individual
450 Commack Road
Deer Park, NY  11729
                                        By:________________________
                                           Susan Blancato

Address for Notice:                     MM(2) GROUP, INC.
                                        [Limited to Paragraphs 2.2,
                                        3.2(a)(v), 4.3(b) and 6.3 only]
5 Regent Street  Suite 520
Livingston, NJ 07039
                                        By:________________________
                                           Mark Meller
                                           President

Address for Notice:                     GENOTEC ACQUISITION CORP.
                                        a New Jersey corporation
5 Regent Street  Suite 520
Livingston, NJ 07039
                                        By:________________________
                                           Mark Meller
                                           President

                                       14
<PAGE>

                                  Schedule 2.1

                                PURCHASED ASSETS

A)   All of the accounts receivable, inventories, cash received as customer
     deposits (work-in-process), capitalized leases, other deposits, prepaid
     expenses, patents, trademarks and other intangible assets (except
     goodwill), notes receivable and all other assets except goodwill and cash
     of any other type. Also included in the acquisition shall be all current
     customers, all past customers from the past 24 months prior to the closing
     date, all customer lists and contact information, the name of the company
     ("Genotec Nutritionals, Inc." and any other current or prior trade names
     ever used by Seller), customer contracts, logos and all proprietary data,
     records and files and any other material currently utilized or reasonably
     necessary for the continued operation of the business.

B)   All valid and disclosed existing leases for equipment.

C)   Valid purchase orders issued in the ordinary course of business.

                                       15
<PAGE>

                                  Schedule 2.2

                               SELLER'S DESIGNEES

     Seller hereby directs MM2 Group, Inc. to issue an aggregate of 10 million
     shares of MM(2) Group, Inc. Class A Common Stock to the following
     individuals and/or entities:

     George Kontonotas                          4,581,500 shares
     Joseph Freedman                            2,992,000 shares
     Susan Blancato                             1,776,500 shares
     Michael Logerfo                              500,000 shares
     Maureen McLaughlin                            80,000 shares
     Paula Daddone                                 40,000 shares
     Maureen Bridges                               15,000 shares
     Robert Blancato                               15,000 shares

                                       16
<PAGE>

                                  Schedule 2.3

                               ASSUMED LIABILITIES

o    Accounts payable and customer deposits;
o    Equipment leases;
o    No other liabilities of any type, whether disclosed or undisclosed,
     will be assumed, including, but not limited to accrued expenses, unpaid
     vacation days, unpaid sick days and other similar short terms payables

                                       17
<PAGE>

                                  Schedule 2.4

                          SELLER'S ACCOUNT RECEIVABLES

                                       18
<PAGE>

                                  Schedule 2.5

                            SELLER'S ACCOUNTS PAYABLE

                                       19
<PAGE>

                                  Schedule 2.6

                                  Leased Assets

                                       20
<PAGE>

                              Schedule 3.2.(a)(iv)

                      Secretary's Certificate of the Seller

                                       21
<PAGE>

                               Schedule 3.2(a)(v)

                   Officer's Incumbency Certificate of Seller

                                       22
<PAGE>

                              Schedule 3.2(b)(vi)

                      Secretary's Certificate of the Buyer

                                       23
<PAGE>

                              Schedule 3.2(b)(vii)

                    Officer's Incumbency Certificate of Buyer

                                       24
<PAGE>

                                Schedule 4.6 (b)

                              INTELLECTUAL PROPERTY

All current customers, all past customers from the past 24 months prior to the
closing date, all customer lists and contact information, the name of the
company ("Genotec Nutritionals, Inc." and any other current or prior trade names
ever used by Genotec Nutritionals), customer contracts, logos and all
proprietary data, records and files and any other material currently utilized or
reasonably necessary for the continued operation of the business.

                                       25EXHIBIT 10.2
                                                                    ------------

                              EMPLOYMENT AGREEMENT
                              --------------------

         EMPLOYMENT AGREEMENT (the "Agreement") dated September 21, 2006 by and
between Genotec Acquisition Corporation ("Genotec" or the "Company"), a New
Jersey corporation with an address at 5 Regent Street, Livingston, NJ 07039 (the
"Company"), and George Kontonotas, an individual having an office at 450 Commack
Road Deer Park, NY 11729 (the "Employee" or "Kontonotas").

                               W I T N E S S E T H
                               -------------------

         WHEREAS, the Company, Genotec Nutritionals, Inc., a Delaware
corporation ("Seller"), George Kontonotas, an individual ("Kontonotas" or
"Employee"), Joseph Freedman, an individual ("Freedman"), Susan Blancato, an
individual ("Blancato"), (Kontonotas, Freedman, and Blancato shall be
collectively referred to herein as the "Shareholders"), MM(2) Group, Inc. , a
New Jersey corporation ("MM2") entered into an Asset Purchase Agreement dated
September 21, 2006 (the "Asset Purchase Agreement"); and

         WHEREAS, the Company desires that Employee be employed by it and render
services to it, and Employee is willing to be so employed and to render such
services to the Company, all on the terms and subject to the conditions
contained herein.

         NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, and other good and valuable consideration, the receipt
sufficiency of which is hereby acknowledged, the parties agree as follows:

1.       EMPLOYMENT
         ----------

         Subject to and upon the terms and conditions contained in this
Agreement, the Company hereby employs Employee, for the period set forth in
Paragraph 2 (subject to the terms and conditions of this Agreement), to render
the services to the Company, its affiliates and/or subsidiaries described in
Paragraph 3.

2.       TERM
         ----

         Employee's term of employment under this Agreement shall commence on
September 21, 2006 (the "Commencement Date") and shall continue for a period
terminating on September 30, 2009 (the "Expiration Date"), unless earlier
terminated under the terms and conditions herein (the "Employment Term").

3.       DUTIES
         ------

               (a) The Employee agrees that he will serve the Company on a
full-time basis faithfully and to the best of his ability as President of the
Company, subject to the
<PAGE>

general supervision of the Board of Directors of the Company. Employee shall be
based in the Company's offices in Deer Park, New York.

               (b) The Employee's duties are subject to change, as determined by
the Company's Board of Directors. The Employee's primary areas of responsibility
include, but are not limited to profit and loss responsibility of the Company

               (c) Employee agrees to abide by all By-Laws and policies of the
Company, as promulgated from time-to-time by the Company.

               (d) Employee will serve as a member of the Company's Management
Committee or as otherwise directed by the Chief Executive Officer of the
Company.

4.       EXCLUSIVE-SERVICES AND BEST EFFORTS
         -----------------------------------

         Employee shall devote his entire working time, attention, best efforts
and ability exclusively to the service of the Company, its affiliates and
subsidiaries during the term of this Agreement. Deviations from this shall
require written approval by the Chief Executive Officer or the Company's Board
of Directors. Employee will be permitted to provide limited management services
to the business of CardioCeuticals LLC only through September 30, 2006. Employee
will, however, be permitted to engage on a limited basis in the business of
brokering raw materials, bulk commodities and ingredients for the benefit of
third parties (the "Brokerage Business"). The Employee will be permitted to
participate in the management of the Brokerage Business so long as the following
conditions are met: (i) the Employee's management participation in the Brokerage
Business takes no more than ten percent (10%) of his time during normal business
hours, (ii) the Brokerage Business shall not compete in any way with the
business of the Company and (iii) the Brokerage Business shall be operated
solely thru Genotec Brokerage Corp., a New Jersey corporation ("Genotec
Brokerage"), a wholly owned subsidiary of MM(2) Group, Inc. For those
transactions of the Brokerage Business which require neither the utilization of
the Genotec Brokerage's facilities nor its financial capabilities, Employee will
receive a commission equal to 100% of the net profit generated on that
transaction. Notwithstanding anything to the contrary: (i) for those customers
of the Brokerage Business listed on Schedule 4.1 herein, the Company shall
receive five percent (5%) of the gross commissions payable to the Employee and
for those customers of the Brokerage Business not listed on Schedule 4.1 herein,
the Company shall receive fifty percent (50%) of the commissions payable to the
Employee (both commissions collectively referred to as the "Company's
Commissions"). In the event that a particular brokerage transaction requires the
utilization of the Genotec Brokerage's finances or facilities, Genotec Brokerage
will be entitled to compensation for its participation. Such participation shall
be negotiated and documented by and between the Board of Directors of the
Company and the Employee prior to the transaction being entered into. The net
profit on any such transaction shall be paid to Employee in the form of a
commission, payable within thirty (30) days after Genotec Brokerage has received
actual payment from the third parties involved in the transaction and Genotec
Brokerage net of the Company's Commissions and/or has further received its
payment for its participation in the transaction.

                                       2
<PAGE>

5.       COMPENSATION
         ------------

               (a) Base Salary. On the Commencement Date and for the next twelve
(12) months following the Commencement Date, the Employee shall receive an
annual salary, payable bi-weekly, in the amount of One Hundred Thousand Dollars
($100,000), subject to all required federal, state and local payroll deductions.
The Employee's base salary shall be increased on each anniversary of the
Commencement Date as deemed appropriate by the Chief Executive Officer with the
approval of the Board of Directors of the Company.

               (b) Additional Compensation. Following the first anniversary of
the Commencement Date, the Employee may be paid a bonus as set forth in
Attachment A herein.

               (c) Stock Options. The Employee shall participate in the
Company's Incentive Stock Option Plan at the sole discretion of the Board of
Directors of the Company.

6.       BUSINESS EXPENSES
         -----------------

         Employee shall be reimbursed for only those business expenses incurred
by him (a) which are reasonable and necessary for Employee to perform his duties
under this Agreement in accordance with policies established from time-to-time
by the Company, and (b) for which Employee has submitted vouchers and/or
receipts.

7.       EMPLOYEE BENEFITS, VACATIONS, PERSONAL DAYS
         -------------------------------------------

During the term of this Agreement:

               (a) The Employee shall participate in the Company's health
insurance program covering himself and his immediate family at no cost to the
Employee.

               (c) The Employee shall be entitled to four (4) weeks of vacation,
sick and/or personal days per annum during the Employment Term beginning on the
Commencement Date, to be planned and taken (where possible) at such times as may
be mutually agreed upon by the Chief Executive Officer of the Company and the
Employee. Vacation may not be carried over from one calendar to the next. Any
vacation earned and not used in the calendar year in which it is earned will be
lost. The Employee shall also be entitled to have off all published holidays of
the Company, as announced on December 31st of each year for the following
calendar year. During the term of this Agreement:

8.       DEATH AND DISABILITY
         --------------------

               (a) The Employment Term shall terminate on the date of Employee's
death, in which event Employee's base salary payable pursuant to Paragraph 5
through

                                       3
<PAGE>

the last day of the month in which the Employee's death did occur shall be paid
to his estate. Employee's estate will not be entitled to any other compensation
upon termination of this Agreement pursuant to this Paragraph 9(a).

               (b) If during the Employment Term, Employee, because of physical
or mental illness or incapacity, shall become substantially unable to perform
the duties and services required of him under this Agreement for a period of
sixty (60) consecutive days or one hundred twenty (120) days in the aggregate,
the Company may, upon at least ten (10) days' prior written notice given at any
time after the expiration of such 60 or 120-day period, as the case may be,
provide Employee with a written notice of its intention to terminate this
Agreement as of such date as may be set forth in the notice. In case of such
termination, Employee shall be entitled to receive his salary payable pursuant
to Paragraph 5, through the date of termination. Employee will not be entitled
to any other compensation upon termination of this Agreement pursuant to this
Paragraph 9(b).

9.       TERMINATION
         -----------

               (a) The Company may terminate the employment of Employee "FOR
CAUSE" during the Employment Term. Upon such termination, except as set forth
herein, the Company shall be released from any and all further obligations under
this Agreement, except that the Company shall be obligated to pay Employee the
unpaid prorated base salary pursuant to Paragraph 5 earned or accrued up through
the day on which Employee is terminated.

               (b) As used herein, the term "FOR CAUSE" shall mean:

                    (i) any material breach of this Agreement by Employee that,
in the case of a breach that may be cured or remedied, is not cured or remedied
to the reasonable satisfaction of the Company within 30 days after written
notice is given by the Company to Employee, setting forth in reasonable detail
the nature of such breach;

                    (ii) Employee's failure to perform his duties and services
hereunder to the reasonable satisfaction of the Chief Executive Officer or the
Board of Directors of the Company that, in the case of any such failure that may
be cured or remedied, is not cured or remedied to the reasonable satisfaction of
the Company within 30 days after notice is given by the Company to Employee,
setting forth in reasonable detail the nature of such failure;

                    (iii) any material act, or material failure to act, by
Employee in bad faith and to the material detriment of the Company; or

                    (iv) commission by Employee of a material act involving
moral turpitude, dishonesty, unethical business conduct, or any other conduct
which significantly impairs the reputation of the Company, its subsidiaries or
affiliates.

                    (v) the conviction of the Employee of a felony, including
the plea of nolo contendre.

                  (c) The Employee may terminate this Agreement if MM2 fails to
contribute the Additional Investment as set forth in Section 6.3(a) of the Asset
Purchase

                                       4
<PAGE>

Agreement within eighteen (18) months from the Closing Date of the Asset
Purchase Agreement.

10.      DISCLOSURE OF INFORMATION AND RESTRICTIVE COVENANT
         --------------------------------------------------

               (a) The Employee acknowledges that the Employee has been informed
that it is the policy of the Company to maintain as secret and confidential all
information

                    (i) relating to the products, processes, designs and/or
systems used by the Company and its Affiliates and

                    (ii) relating to the customers and employees of the Company
and its Affiliates. Confidential information and trade secrets include, but are
not limited to, customer and client lists, price lists, marketing and sales
strategies and procedures, operational and equipment techniques, business plans
and systems, quality control procedures and systems, special projects and
technological research, including projects, research and reports for any entity
or client or any project, research, report or the like concerning sales or
manufacturing or new technology, employee compensation plans and any other
information relating thereto, and any other records, files, drawings,
inventions, discoveries, applications or processes which are not in the public
domain (all the foregoing shall be referred to herein as the "Confidential
Information"). The Employee further acknowledges that such Confidential
Information is of great value to the Company.

         For purposes of this Agreement, "Affiliates" means any person or entity
or group of persons or entities acting together that, directly or indirectly,
through one or more intermediaries, controls, or is controlled by, or is under
common control with, the Company.

         The parties recognize that the services to be performed by the Employee
are special and unique, and that by reason of his employment by the Company, the
Employee has and will acquire Confidential Information as stated above. The
parties confirm that it is reasonably necessary to protect the Company's (and
its Affiliates') goodwill, and accordingly the Employee does agree that the
Employee shall not and will not directly or indirectly (except where authorized
by the Board of Directors of the Company for the benefit of the Company or
agreed in writing by the Company and the Employee):

                    A. At any time during his employment by the Company or after
the Employee ceases to be employed by the Company, divulge to any persons, firms
or corporations, other than the Company (hereinafter referred to collectively as
"third parties"), or use or allow or cause or authorize any third parties to
use, any such confidential information; and

                    B. At any time during his employment by the Company and for
a period of twenty four (24) months after the Employee ceases to be employed by
the Company, solicit or cause or authorize directly or indirectly to be
solicited, for or on behalf of the Employee or third parties, in connection with
any Competitive Activity

                                       5
<PAGE>

within two (2) years prior to the cessation of his employment hereunder,
customers of the Company or its affiliates; and

                    C. At any time during his employment by the Company and for
a period of twenty four (24) months after the Employee ceases to be employed by
the Company, accept or cause or authorize directly or indirectly to be accepted,
for or on behalf of the Employee or third parties, any business in connection
with any Competitive Activity from any such customers of the Company or its
affiliates; and

                    D. At any time during his employment by the Company and for
a period of twenty four (24) months after the Employee ceases to be employed by
the Company, solicit or cause or authorize directly or indirectly to be
solicited for employment, for or on behalf of the Employee or third parties, any
persons (excluding any individuals residing in the same immediate primary
residence as the Employee, and/or the Employee's immediate family) who were at
any time within one year prior to the cessation of his employment hereunder,
employees of the Company or its affiliates; and

                    E. At any time during his employment by the Company and for
a period of twenty four (24) months after the Employee ceases to be employed by
the Company, employ or cause or authorize directly or indirectly to be employed,
for or on behalf of the Employee or third parties, any such employees of the
Company or its affiliates.

                    F. Notwithstanding anything to the contrary, the Employee
will be permitted to provide limited management services to the business of
CardioCeuticals LLC only through September 30, 2006.

               (b) The Employee agrees that, upon the expiration of his
employment by the Company for any reason, the Employee shall forthwith deliver
up to the Company any and all records, drawings, notebooks, keys and other
documents and material, and copies thereof in his possession or under his
control which is the property of the Company or which relate to any confidential
information or any discoveries of the Company.

               (c) The Employee agrees that any breach or threatened breach by
the Employee of any provision of Paragraphs 10 and 11 shall entitle the Company,
in addition to any other legal remedies available to it, to enjoin such breach
or threatened breach through any court of competent jurisdiction. The parties
understand and intend that each restriction agreed to by the Employee herein
above shall be construed as separable and divisible from every other
restriction, and that the unenforceability, in whole or in part, of any
restriction will not affect the enforceability of the remaining restrictions,
and that one or more or all of such restrictions may be enforced in whole or in
part as the circumstances warrant.

               (d) For the purposes of this Section, the term "Company" shall
mean and include any and all subsidiaries, parents and affiliated corporations
of the Company in existence from time to time, for which the Company has
operational control.

                                       6
<PAGE>

               (e) Employee will not induce or persuade other employees of the
Company to join him in any activity prohibited by Paragraph 10 or 11.

               (f) This Paragraph 10 and Paragraphs 11, 12, 13, 14, 19 and 20
shall survive the expiration or termination of the Agreement for any reason,
except Paragraph 10.B, 10.C, 10.D and 10.E shall terminate upon: (i) the
Employee's resignation and MM2 failing to contribute the Additional Investment
as set forth in Section 6.3(a) of the Asset Purchase Agreement within eighteen
(18) months from the Closing Date of the Asset Purchase Agreement or (ii) the
Company failing to pay the Employee his Base Salary and/or commissions on a
timely basis or (iii) the wrongful termination of the Employee by the Company as
determined by a court of competent jurisdiction.

               (g) It is expressly agreed by Employee that the nature and scope
of each of the provisions set forth in Paragraphs 10 and 11 are reasonable and
necessary. If, for any reason, any aspect of these provisions as they apply to
Employee is determined by a court of competent jurisdiction to be unreasonable
or unenforceable, the provisions shall only be modified to the minimum extent
required to make the provisions reasonable and/or enforceable, as the case may
be. Employee acknowledges and agrees that his services are of a unique character
and expressly grants to the Company or any subsidiary, successor or assignee of
the Company, the right to enforce the provisions above through the use of all
remedies available at law or in equity, including, but not limited to,
injunctive relief.

               (h) Notwithstanding anything to the contrary, the Employee may
continue to conduct and operate his Brokerage Business with those clients and/or
customers of the Seller that were also clients and/or customers of the Brokerage
Business prior to the Closing Date of the Asset Purchase Agreement.

               (i) For purposes of this Section 10, "Competitive Activity" shall
mean any activity relating to, in respect of or in connection with, directly or
indirectly, any and all products that the Seller offered to its customers or
anticipated to offer to its customers immediately prior to the Closing Date of
the Asset Purchase Agreement or two (2) years prior to the Employee's employment
terminated, except: (i) for the Brokerage Business conducted by Kontonotas prior
to the Closing date and (ii) the business of CardioCeuticals LLC and [the mail
order business] only through September 30, 2006.

11.      COMPANY PROPERTY
         ----------------

               (a) Any products, patents, inventions, discoveries, applications,
processes or designs, devised, planned, applied, created, discovered or invented
by Employee in the course of Employee's employment under this Agreement and
which pertain to any aspect of the Company's or its respective subsidiaries' or
affiliates' businesses shall be the sole and absolute property of the Company,
and Employee shall make prompt report thereof to the Company and promptly
execute any and all documents reasonably requested to assure the Company the
full and complete ownership thereof.

               (b) All records, files, lists, including computer generated
lists, drawings, documents, equipment and similar items relating to the
Company's business which

                                       7
<PAGE>

Employee shall prepare or receive from the Company shall remain the Company's
sole and exclusive property. Upon the expiration of this Agreement, or, if
earlier, upon demand by the Company, Employee shall promptly return to the
Company all property of the Company in his possession. Employee further
represents that he will not copy or cause to be copied, print out or cause to be
printed out any software, documents or other materials originating with or
belonging to the Company. Employee covenants that, upon termination of his
employment with the Company, he will not retain in his possession any such
software, documents or other materials.

12.      REMEDY
         ------

         It is mutually understood and agreed that Employee's services are
special, unique, unusual, extraordinary and of an intellectual character giving
them a peculiar value, the loss of which cannot be reasonably or adequately
compensated in damages in an action at law. Accordingly, in the event of any
breach of this Agreement by Employee, including, but not limited to, the breach
of the non-disclosure, non-solicitation and non-compete clauses under Paragraphs
10 and 11 hereof, the Company shall be entitled to equitable relief by way of
injunction or otherwise in addition to damages the Company may be entitled to
recover. Nothing herein shall be deemed to restrict any remedy available to
Employee for breach of the Agreement by the Company.

13.      REPRESENTATIONS AND WARRANTIES OF EMPLOYEE AND THE COMPANY
         ----------------------------------------------------------

               (a) In order to induce the Company to enter into this Agreement,
Employee hereby represents and warrants to the Company as follows: (i) Employee
has the legal capacity and unrestricted right to execute and deliver this
Agreement once to perform all of his obligations hereunder: (ii) the execution
and delivery of this Agreement by Employee and the performance of his
obligations hereunder will not violate or be in conflict with any fiduciary or
other duty, instrument, agreement, document, arrangement or other understanding
to which Employee is a party or by which he is or may be bound or subject; and
(iii) Employee is not a party to any instrument, agreement, document,
arrangement or other understanding with any person (other than the Company)
requiring or restricting the use or disclosure of any Confidential Information
or the provision of any employment, consulting or other services.

               (b) The Company hereby represents and warrants to Employee, as
follows: (i) the execution, delivery, and performance of this Agreement has been
duly authorized by all necessary corporate action of the Company; and (ii) this
Agreement constitutes the valid and binding obligation of the Company,
enforceable in accordance with its terms, except that such enforcement may be
subject to any bankruptcy, insolvency, reorganization, fraudulent transfer or
other laws, now or hereafter in effect, relating to or limiting creditors'
rights generally.

14.      NOTICES
         -------

         All notices given hereunder shall be in writing and shall be deemed
upon delivery or attempted delivery, if sent by registered or certified mail,
return receipt requested, or via overnight courier addressed to Employee at his
address set forth on the first page of

                                       8
<PAGE>

this Agreement, or to the Company at its address set forth on the first page of
this Agreement, Attention: Chief Executive Officer, with a copy to Meritz &
Muenz LLP, 2021 O Street, NW, Washington, DC 20036, Attention: Lawrence A.
Muenz, or at such address as such party shall have designated by a notice given
in accordance with this Paragraph 14, or when actually received by the party for
whom intended, if sent by any other means..

15.      ENTIRE AGREEMENT
         ----------------

         This Agreement constitutes the entire understanding of the parties with
respect to its subject matter and no change, alteration or modification hereof
may be made except in writing signed by the parties hereto. Any prior or other
agreements, promises, negotiations or representations not expressly set forth in
this Agreement are of no force or effect.

16.      SEVERABILITY
         ------------

         If any provision of this Agreement shall be unenforceable under any
applicable law, then notwithstanding such unenforceability, the remainder of
this Agreement shall continue in full force and effect.

17.      WAIVERS, MODIFICATIONS, ETC.
         ----------------------------

         No amendment, modification or waiver of any provision of this Agreement
shall be effective unless the same shall be in writing and signed by each of the
parties hereto, and then such waiver or consent shall be effective only in the
specific instance and for the specific purpose for which given.

18.      ASSIGNMENT
         ----------

         Neither this Agreement, nor any of Employee's rights, powers, duties or
obligations hereunder, may be assigned by Employee. This Agreement shall be
binding upon and inure to the benefit of Employee and his heirs and legal
representatives and the Company and its successors and assigns. Successors of
the Company shall include, without limitation, any corporation or corporations
acquiring, directly or indirectly, all or substantially all of the assets of the
Company, whether by merger, consolidation, purchase, lease or otherwise, and
such successor shall thereafter be deemed "the Company" for the purpose hereof.

19.      APPLICABLE LAW
         --------------

         This Agreement shall be deemed to have been made, drafted, negotiated
and the transactions contemplated hereby consummated and fully performed in the
State of New York and shall be governed by and construed in accordance with the
laws of the State of New York, without regard to the conflicts of law rules
thereof. Nothing contained in this Agreement shall be construed so as to require
the commission of any act contrary to law, and whenever there is any conflict
between any provision of this Agreement and any statute, law, ordinance, order
or regulation, contrary to which the

                                       9
<PAGE>

parties hereto have no legal right to contract, the latter shall prevail, but in
such event any provision of this Agreement so affected shall be curtailed and
limited only to the extent necessary to bring it within the legal requirements.

20.      JURISDICTION AND VENUE
         ----------------------

         It is hereby irrevocably agreed that all actions, suits or proceedings
between the Company and Employee arising out of, in connection with or relating
to this Agreement shall be exclusively heard and determined in, and the parties
do hereby irrevocably submit to the exclusive jurisdiction of the Supreme Court
of New York in Suffolk County, New York or the Federal District Court in the
district in which the Company's principal offices are located. The parties also
agree that a final judgment in any such action, suit or proceeding shall be
conclusive and may be enforced in other jurisdictions by suit on the judgment or
in any other manner provided by law. The parties hereby unconditionally waive
any objection which either of them may now or hereafter have to the venue of any
such action, suit or proceeding brought in any of the aforesaid courts, and
waive any claim that any such action, suit or proceeding brought in any such
court has been brought in an inconvenient forum.

21.      FULL UNDERSTANDING
         ------------------

         Employee represents and agrees that he fully understands his right to
discuss all aspects of this Agreement with his private attorney, that to the
extent, if any, that he desired, he availed himself of this right, that he has
carefully read and fully understands all of the provisions of this Agreement,
that he is competent to execute this Agreement. that his willingness to execute
this Agreement has not been obtained by any duress and that he freely and
voluntarily enters into it, and that he has read this document in its entirety
and fully understands the meaning, intent and consequences of this document
which is that it constitutes an agreement of employment.

                                       10
<PAGE>

         IN WITNESS WHEREOF, the parties hereto have executed this Agreement as
of the date first written above.

GENOTEC ACQUISITION CORPORATION             GEORGE KONTONOTAS

By:                                         By:
   ---------------------------                 -------------------------
     Mark Meller
     Chairman of the Board and
     Chief Executive Officer

GENOTEC BROKERAGE CORP.
[limited to Paragraph 4 only]

By:
   ---------------------------
     Mark Meller
     Chairman of the Board and
     Chief Executive Officer

                                       11
<PAGE>

                                                                    ATTACHMENT A

An annual cash bonus will be paid to the Employee based upon the gross profit of
the Company. The amount paid in the aggregate to the Chief Executive Officer,
Vice President-Product Development, and Vice President - Administration, as a
group, will be based on the gross profit of the Company. The formula for such
bonus shall be as follows:

Year                                    Bonus
--------------------------------------------------------------------------------
Balance of 2006                         3% of gross profit in excess of $375,000

2007                                    3% of gross profit in excess of $400,000

2008                                    3% of gross profit in excess of $450,000

Balance of 2009 (through
  September 30, 2009)                   3% of gross income in excess of $500,000

In the event that Employee's contract is not renewed subsequent to the
Expiration Date, Employee shall be entitled to a payment equal to 3% of the
gross profit generated during the twelve (12) month period following the
Expiration Date. This shall be a one-time payment, payable at the Company's
discretion in either cash and/or stock.

Payment of the bonus will be made at such time that the Company has sufficient
cash reserves to make such payment. It is expressly understood that MM2 will not
provide funds to the Company for the purpose of paying these bonuses.

The annual bonus pool as noted above shall be paid 49% to George Kontonotas, 32%
to Joseph Freedman, and 19% to Susan Blancato.

In addition, the Chief Executive Officer, Vice President-Product Development,
and Vice President - Administration, as a group, shall receive an additional
cash bonus equal to fifteen percent (15%) of the annual income, in excess of
$30,000, earned from the sales of Misoprostol and the "pain management patch',
FDA approved, manufactured by Lavipharm Laboratories, Inc. This commission shall
be paid for a period of ten 910) years from the date hereof. This additional
annual cash bonus shall be paid 49% to George Kontonotas, 32% to Joseph
Freedman, and 19% to Susan Blancato.

                                       12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00110-of-00352.parquet"}]]